Doctors have noted improved survival rates in patients with refractory metastatic colorectal cancer.
Researchers from MD Anderson Cancer Centerat the University of Texas reported the results of a new study on colorectal cancer. Targeted therapy with frutinib has been shown to improve overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.
OS was 7.4 months in the patient group,who took frutinib, compared with 4.8 months in the placebo group. At the same time, the median PFS was 3.7 months in the group of patients on frutinib compared to 1.8 months in the placebo group.
in patients with refractory metastaticThere are very limited treatment options for colorectal cancer,” explains Arvind Dasari, Principal Investigator, MD and Associate Professor of Gastrointestinal Medical Oncology. “The results of the new study are very encouraging and confirm that fructinib can be used to treat patients who previously had no other options.”
Randomized clinical phase trialIII was conducted at 153 centers in the United States, Europe, Japan and Australia. In a double-blind study, researchers evaluated treatment with the new oral drug frutinib, a small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) tyrosine kinases, in combination with supportive care versus placebo and supportive care in patients previously treated with intensive care. treatment for resistant metastatic colorectal cancer.
According to the American Cancer Society,Colorectal cancer is the second leading cause of cancer death in men and women combined. Despite advances in treatment, patients with metastatic colorectal cancer still have poor long-term survival rates. After patients undergo therapy, they usually live only four to five months. Therefore, there is a great need for alternative therapies.
Read more:
The space plane will deliver cargo to the ISS and land at a regular "airport"
The star approached the black hole and it was torn apart: scientists observed this from three telescopes
Scientists have found traces of genetic mutations in the blood of every person who has been in space
Cover photo: NIH Image Gallery